Ulcerative Colitis - Drug Pipeline Landscape, 2023

Ulcerative Colitis - Drug Pipeline Landscape, 2023

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), which is caused by reactions of the immune system and results in inflammation and ulcers on the inner lining of the colon and rectum.

There is no recognized etiology for ulcerative colitis. However, specialists think that immune system dysfunction, genetics, modifications to the usual gut flora, and environmental factors may all be at play.

The primary symptoms of active disease are abdominal pain and diarrhoea mixed with blood, due to which fever, anaemia, and weight loss occur. Additional symptoms include faecal incontinence, increased frequency of bowel movements, mucus discharge, and nocturnal defecations.

The diagnosis of ulcerative colitis involves colonoscopy and tissue biopsies. Specific tests include CBP, electrolyte studies, kidney function tests, liver function tests, and imaging, including X-rays and CT scans.

The initial treatment involves medications for remission, followed by the administration of maintenance medications to prevent a relapse. Medications include 5-ASA drugs, immune suppressants, biologics, and other medications like anti-diarrheal and pain relievers. In severe cases, surgery is preferable, which involves proctocolectomy and ileoanal anastomosis (J-pouch) surgery.

Report Highlights

Global Insight Service’s, Ulcerative Colitis - Drug Pipeline Landscape, 2023 report provides an overview of the Ulcerative Colitis pipeline drugs. This report covers detailed insights on Ulcerative Colitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Ulcerative Colitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.